Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1
Screening for neuroendocrine tumors (NETs) in patients with multiple endocrine neoplasia type 1 (MEN1) is recommended to detect primary and metastatic tumors, which can result in significant morbidity and mortality. The utility of somatostatin receptor imaging (68)Gallium-DOTATATE PET/CT in patients with MEN1 is not known. The aim of this study was to prospectively determine the accuracy of (68)Gallium-DOTATATE PET/CT vs (111)In- pentetreotide single-photon emission CT (SPECT)/CT and anatomic imaging in patients with MEN1. We performed a prospective study comparing (68)Gallium-DOTATATE PET/CT, (111)In-pentetreotide SPECT/CT, and triphasic CT scan to clinical, biochemical, and pathologic data in 26 patients with MEN1. (68)Gallium-DOTATATE PET/CT detected 107 lesions; (111)In-pentetreotide SPECT/CT detected 33 lesions; and CT scan detected 48 lesions. Lesions detected on (68)Gallium-DOTATATE PET/CT had high standard uptake value (SUV)(max) (median SUV(max) = 72.8 [range 19 to 191]). In 7 of the 26 patients (27%), (68)Gallium-DOTATATE PET/CT was positive, with a negative (111)In-pentetreotide SPECT/CT, and in 10 patients (38.5%), additional metastases were detected (range 0.3 cm to 1.5 cm). In 8 of the 26 patients (31%), there was a change in management recommendations as a result of the findings on (68)Gallium-DOTATATE PET/CT that were not seen on (111)In-pentetreotide SPECT/CT and CT scan. (68)Gallium-DOTATATE PET/CT is more sensitive for detecting NETs than (111)In-pentetreotide SPECT/CT and CT scan in patients with MEN1. This imaging technique should be integrated into radiologic screening and surveillance of patients with MEN1 because it can significantly alter management recommendations..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:221 |
|---|---|
| Enthalten in: |
Journal of the American College of Surgeons - 221(2015), 2, Seite 509 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sadowski, Samira M [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1964975301 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1964975301 | ||
| 003 | DE-627 | ||
| 005 | 20230714163208.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1964975301 | ||
| 035 | |a (DE-599)GBVOLC1964975301 | ||
| 035 | |a (PRQ)p597-e3826f1e4216836c435ccb449fa3494754579b9d2f99bfa9d53b11a40be8cbb20 | ||
| 035 | |a (KEY)0038672320150000221000200509resultsof68galliumdotatatepetctscanninginpatientsw | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Sadowski, Samira M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1 |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Screening for neuroendocrine tumors (NETs) in patients with multiple endocrine neoplasia type 1 (MEN1) is recommended to detect primary and metastatic tumors, which can result in significant morbidity and mortality. The utility of somatostatin receptor imaging (68)Gallium-DOTATATE PET/CT in patients with MEN1 is not known. The aim of this study was to prospectively determine the accuracy of (68)Gallium-DOTATATE PET/CT vs (111)In- pentetreotide single-photon emission CT (SPECT)/CT and anatomic imaging in patients with MEN1. We performed a prospective study comparing (68)Gallium-DOTATATE PET/CT, (111)In-pentetreotide SPECT/CT, and triphasic CT scan to clinical, biochemical, and pathologic data in 26 patients with MEN1. (68)Gallium-DOTATATE PET/CT detected 107 lesions; (111)In-pentetreotide SPECT/CT detected 33 lesions; and CT scan detected 48 lesions. Lesions detected on (68)Gallium-DOTATATE PET/CT had high standard uptake value (SUV)(max) (median SUV(max) = 72.8 [range 19 to 191]). In 7 of the 26 patients (27%), (68)Gallium-DOTATATE PET/CT was positive, with a negative (111)In-pentetreotide SPECT/CT, and in 10 patients (38.5%), additional metastases were detected (range 0.3 cm to 1.5 cm). In 8 of the 26 patients (31%), there was a change in management recommendations as a result of the findings on (68)Gallium-DOTATATE PET/CT that were not seen on (111)In-pentetreotide SPECT/CT and CT scan. (68)Gallium-DOTATATE PET/CT is more sensitive for detecting NETs than (111)In-pentetreotide SPECT/CT and CT scan in patients with MEN1. This imaging technique should be integrated into radiologic screening and surveillance of patients with MEN1 because it can significantly alter management recommendations. | ||
| 540 | |a Nutzungsrecht: © Published by Elsevier Inc. | ||
| 650 | 4 | |a Positron-Emission Tomography - methods | |
| 650 | 4 | |a Radiopharmaceuticals - diagnostic use | |
| 650 | 4 | |a Multiple Endocrine Neoplasia Type 1 - radiography | |
| 650 | 4 | |a Somatostatin - diagnostic use | |
| 650 | 4 | |a Multiple Endocrine Neoplasia Type 1 - radionuclide imaging | |
| 650 | 4 | |a Somatostatin - analogs & derivatives | |
| 650 | 4 | |a Organometallic Compounds - diagnostic use | |
| 700 | 1 | |a Millo, Corina |4 oth | |
| 700 | 1 | |a Cottle-Delisle, Candice |4 oth | |
| 700 | 1 | |a Merkel, Roxanne |4 oth | |
| 700 | 1 | |a Yang, Lily A |4 oth | |
| 700 | 1 | |a Herscovitch, Peter |4 oth | |
| 700 | 1 | |a Pacak, Karel |4 oth | |
| 700 | 1 | |a Simonds, William F |4 oth | |
| 700 | 1 | |a Marx, Stephen J |4 oth | |
| 700 | 1 | |a Kebebew, Electron |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Surgeons |d [Philadelphia, Pa.] : Wolters Kluwer Health, 1994 |g 221(2015), 2, Seite 509 |w (DE-627)181995921 |w (DE-600)1181115-8 |w (DE-576)038263408 |x 1072-7515 |7 nnns |
| 773 | 1 | 8 | |g volume:221 |g year:2015 |g number:2 |g pages:509 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26206648 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 221 |j 2015 |e 2 |h 509 | ||